SCHEMBL8296803

SCHEMBL8296803

COc1ccc(Cl)cc1-c1ccc(NC(=O)c2c(F)cccc2F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IL2 P60568 4/20 0.56
▸ POLB P06746 2/20 0.55
▸ ALDH1A1 P00352 5/20 0.54
▸ RAB9A P51151 3/20 0.53
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ GLA P06280 1/20 0.51
▸ MAPT P10636 3/20 0.51
▸ NPC1 O15118 3/20 0.51
▸ HPGD P15428 2/20 0.51
▸ GAA P10253 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ CRHBP P24387 1/20 0.51
▸ CRHR2 Q13324 1/20 0.51
▸ STIM1 Q13586 1/20 0.51
▸ ORAI1 Q96D31 1/20 0.51
▸ HSD17B10 Q99714 2/20 0.50
▸ KCNMA1 Q12791 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1828445 0.88 STIM1 (0.65) IL2POLBALDH1A1RAB9AMEN1
SCHEMBL1825721 0.87 ALDH1A1 (0.57) POLBALDH1A1RAB9AMEN1KMT2A
SCHEMBL16363203 0.86 RAB9A (0.51) IL2POLBALDH1A1RAB9AMEN1
SCHEMBL1825939 0.84 IL2 (0.76) IL2RAB9ASMN1; SMN2MAPTNPC1
SCHEMBL1827167 0.83 ALDH1A1 (0.60) POLBALDH1A1RAB9AMEN1KMT2A
SCHEMBL4766505 0.81 IL2 (0.53) IL2POLBRAB9AMAPTGAA
SCHEMBL8263206 0.80 IL2 (0.53) IL2ALDH1A1RAB9ANPC1LMNA
SCHEMBL4769818 0.80 IL2 (0.58) IL2POLBALDH1A1RAB9AMEN1
SCHEMBL1823693 0.79 ORAI1 (0.81) POLBALDH1A1RAB9AMEN1KMT2A
SCHEMBL16805017 0.78 KDR (0.53) IL2POLBALDH1A1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150005320-A9 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2015-01-01 — — US disclosed
US-20150005320-A9 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2015-01-01 — — US disclosed
US-20140107134-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-04-17 — — US disclosed
US-20140107134-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-04-17 — — US disclosed
EP-2319516-A1 Compounds for treating inflammatory and autoimmune disorders Synta Pharmaceuticals Corp. (US) 2011-05-11 — — EP disclosed
WO-2005009954-A2 METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 — — WO disclosed
WO-2005009539-A2 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS, CORP. (US) 2005-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140107134-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCR2, CXCL8, CCR9 IL2 27/4885POLB 4276/4885ALDH1A1 1952/4885
US-20150005320-A9 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CXCR2, CXCL8, CCR9 IL2 27/4885POLB 4276/4885ALDH1A1 1952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback